Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
F is an orotomide a novel class of antifungals which
2024-07-10

F901318 is an orotomide, a novel class of antifungals, which inhibits pyridine biosynthesis by blocking dihydroorotate dehydrogenase (URA1) activity [137]. Although this pathway is conserved in humans, human URA1 is only 20% identical to its fungal homolog and it is inhibited 2000-fold less effectiv
-
Introduction Alzheimer s disease AD is a complex neurologica
2024-07-09

Introduction Alzheimer's disease (AD) is a complex neurological disorder characterized by a progressive dementia resulting from synapse failure (Selkoe, 2002, Tanzi, 2005). The amyloid hypothesis maintains that the pivotal event in AD is the production of amyloid-β (Aβ) peptides following the prote
-
For patients who have taken advantage of the
2024-07-09

For patients who have taken advantage of the anti-TKIs and whose follow-up has been succeeded, some partial response has been noticed with 45% (9/20) for gefitinib, 39% (9/23) for erlotinib and 56.5% (13/23) for crizotinib. A disease progression has also been observed with 35% (7/20) for gefitinib,
-
An important observation in our study
2024-07-09

An important observation in our study is the lack of effect of paroxetine pretreatment alone on β2AR membrane expression, which suggests that paroxetine, and pharmacologic inhibition of GRK2 in general, does not directly induce changes in receptor dynamics. Rather, the decreased ligand-induced β-ar
-
br Results br Discussion Dopamine regulates behavioral
2024-07-09

Results Discussion Dopamine regulates behavioral responses to nicotine in Drosophila (Bainton et al., 2000), but neurochemical measurements of dopamine after nicotine stimulation had not been made. Here, we demonstrate for the first time that the stimulation of nAChRs causes dopamine release i
-
Although experiments on animals and cells indicate that
2024-07-09

Although experiments on animals and cells indicate that antioxidant and free radical scavenging agents have protective effects against brain damage, the results of preclinical trials are not as encouraging. Edaravone is a type of free radical scavenging drug that was first used as a neuroprotective
-
HT receptors are distributed throughout the brain within
2024-07-09

5-HT3 receptors are distributed throughout the brain, within the brainstem (e.g., nucleus tractus solitarius, area postrema and spinal trigeminal nucleus) and QNZ (e.g., hippocampus, amygdala, nucleus accumbens, putamen and caudate) (Abi-Dargham et al., 1993, Barnes et al., 1989, Bufton et al., 1993
-
In this study significant reduction in the HCO content
2024-07-09

In this study, significant reduction in the HCO3− content in sham-operated and testosterone-treated rats following bafilomycin A1 administration suggested that V-ATPase could be involved in mediating the decrease in vas deferens fluid HCO3− content, most probably due to the increase in H+ secretion
-
Our results clearly demonstrate that inhibition of ATM
2024-07-08

Our results clearly demonstrate that inhibition of ATM pathway activation results in resistance to Vγ2Vδ2 T cell-mediated cell death. Therefore, enhancing ATM activation along with Vγ2Vδ2 T cell treatment would promote the cytotoxicity of resistant ovarian cancer cells. To our knowledge, this is the
-
In the pituitary of R quelen mRNA
2024-07-08

In the pituitary of R. quelen mRNA levels of cyp19a1b were found to be higher in males than females, suggesting a sex-specific function, and perhaps a local action to regulate gonadotropins or other pituitary hormone secretion (Olivereau and Callard, 1985; Zhang et al., 2014). Interestingly, the hig
-
br Materials and method br Results br Discussion Although se
2024-07-08

Materials and method Results Discussion Although several studies have showed the crude extracts of K. senegalensis possessed the anti-inflammatory and hypertensive activities (Olayinka et al., 1992). However, the anti-inflammatory effect and underlying molecular mechanisms of its bioactive
-
Consideration of the rate of product
2024-07-08

Consideration of the rate of product formation at different substrate concentrations and estimation of Michaelis-Menten parameters gives some insight into the possible mechanisms underlying the observed decreases in enzyme activity. Estimates based on two-substrate concentrations lack precision and
-
Data used in preparation of this article
2024-07-08

Data used in preparation of this article were obtained from the ADNI database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing o
-
In this study Rb increased the phosphorylation of
2024-07-08

In this study, Rb1 increased the phosphorylation of p38 MAPK and Akt and macrophage phagocytosis of bacteria in mouse lung cells, consistent with the in vitro results. A recent study showed that Rb1 diminished the severity of lung injury in rats exposed to LPS. Rb1 inhibited the LPS-induced increase
-
Atorvastatin Calcium mg In the late s Solvay
2024-07-08

In the late ‘90s, Solvay Pharmaceuticals discontinued the Phase 2 development of a promising potent and highly selective A1AR antagonist based on the pyrrolopyrimidine scaffold, SLV320 [43] (2, Chart 1, also named derenofylline; Ki hA1AR = 1 nM), for the treatment of acute heart failure [24]. In the
16203 records 133/1081 page Previous Next First page 上5页 131132133134135 下5页 Last page